IGF-I and Free Fatty Acids Isn Glucose Metabolism in Acromegaly
The Role of Insulin-like Growth Factor-I (IGF-I) and Free Fatty Acids in Insulin Resistance, Insulin Secretion and Glucose Metabolism Abnormalities in Acromegaly
1 other identifier
observational
16
1 country
1
Brief Summary
Background Glucose metabolism abnormalities are frequent in acromegaly. Insulin resistance (IR) correlates with the intensity of acromegaly and Insulin-like Growth factor-I (IGF-I) correlates better with IR than growth hormone (GH). Insulin secretion (IS) is significantly reduced in hyperglycemic acromegalics as compared with those with normal glucose levels. IS is independent of acromegaly intensity. The aim of this study is to show that in active acromegaly: 1) IGF-I does not cause IR but is just a better marker of acromegaly intensity than GH; 2) high GH levels induce IR through free fatty acids (FFA); 3) hyperglycemia is caused by a defficient IS on a background of IR. Methods Intensity of acromegaly will be assessed using serum levels of GH, IGF-I and IGF binding globulin-3. IR and IS will be assessd using an intravenous glucose tolerance test acording to Bergman model. FFA will be directly measured in plasma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Mar 2014
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2014
CompletedFirst Submitted
Initial submission to the registry
March 7, 2014
CompletedFirst Posted
Study publicly available on registry
March 11, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2019
CompletedAugust 21, 2019
August 1, 2019
5 years
March 7, 2014
August 20, 2019
Conditions
Outcome Measures
Primary Outcomes (3)
The correlation coefficient between IGFBP-3 and insulin resistance assessed using Bergman model is non-inferior to the correlation coefficient between IGF-I and insulin resistance
2 years
Free fatty acids correlates significantly with insulin resistance assessed using Bergman model
2 years
Disposition index calculated using Bergman model is significantly reduced in subjects with glucose intolerance than in subjects with normal glucose tolerance
2 years
Secondary Outcomes (5)
GH, IGF-I and IGFBP-3 significantly correlates with insulin resistance calculated using Bergman model
2 years
GH, IGF-I and IGFBP-3 significantly correlates with free fatty acids
2 years
GH, IGF-I and IGFBP-3 does not correlate with insulin sensitivity calculated using Bergman model
2 years
GH, IGF-I and IGFBP-3 does not correlate with disposition index
2 years
Disposition index after reduction of acromegaly activity by various treatments
3 months after surgery or start of medical treatment
Eligibility Criteria
The study will prospectively include patients with active acromegaly assessed in a tertiary center. All patients who meet inclusion and exclusion criteria will be invited consecutively to participate in the study until the proposed number of patients is reached.
You may qualify if:
- active acromegaly based on following criteria: minimum GH in oral glucose tolerance test (OGTT) over 1 ng/mL and serum IGF-I over upper limit of normal for age and sex
- age between 18 and 65 years old
You may not qualify if:
- more than one previous pituitary surgical intervention for acromegaly
- present medical treatment for acromegaly (somatostatin analogs, GH-receptor blockers, dopaminergic agonists)
- previous pituitary radiotherapy
- present medical treatment for hyperglycemia (oral antidiabetic drugs, insulin, etc)
- pituitary failure, treated or not
- medical or surgical conditions which, in the oppinion of the principal investigator, could impact on study results or patient's safety
- fasting blood glucose over 200 mg/dL or HbA1c over 8%.
- body mass index less than 20 or over 35 kg/mp
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
"C. I. Parhon" Institute of Endocrinology
Bucharest, 011863, Romania
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Lecturer, PhD
Study Record Dates
First Submitted
March 7, 2014
First Posted
March 11, 2014
Study Start
March 1, 2014
Primary Completion
March 1, 2019
Study Completion
March 1, 2019
Last Updated
August 21, 2019
Record last verified: 2019-08